Cell Therapies, Biosimilars Boost Biologics Clinical Trials In Korea
South Korean clinical trial data for 2016 reflects the global boom in biologics R&D and the decline in development of synthetic drugs. A series of clinical trial failures by major South Korean pharmaceutical firms may also have weakened overall drug development activities.
You may also be interested in...
Amid repeated calls industry, South Korea decides to pay for Keytruda and Opdivo in its first reimbursement of immuno-oncology drugs, albeit at limited scope. The government is poised to expand reimbursement of IO drugs going forward amid its plan to significantly expand health insurance coverage.
In a recent interview with PharmAsia News, the head of the Korea Clinical Trial Global Initiative stressed the importance of continued government support in boosting the country’s competitiveness in clinical trials, amid narrowing gaps with its Asian rivals. He also talked about why the initiative is focusing on attracting early phase work from foreign firms and what South Korea needs to do to maintain its edge.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.